Nebivolol
| Autor: | Antona J. Wagstaff, Marit D Moen |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Drug
medicine.medical_specialty Heart disease Vasodilator Agents media_common.quotation_subject Adrenergic beta-Antagonists Population Vasodilation Essential hypertension Nebivolol Internal medicine Humans Medicine Benzopyrans Pharmacology (medical) education Antihypertensive Agents media_common Heart Failure education.field_of_study business.industry Antagonist medicine.disease Adrenergic beta-1 Receptor Antagonists Ethanolamines Anesthesia Heart failure Chronic Disease Hypertension Cardiology business medicine.drug |
| Zdroj: | Drugs. 66:1389-1409 |
| ISSN: | 0012-6667 |
| DOI: | 10.2165/00003495-200666100-00007 |
| Popis: | Nebivolol is a third-generation beta-adrenoceptor antagonist. It differs from other beta-adrenoceptor antagonists as it combines highly selective beta(1)-adrenoceptor antagonist properties with nitric oxide-mediated vasodilatory actions and beneficial effects on endothelial function. Nebivolol is approved in Europe and several other countries for the treatment of essential hypertension and in Europe for the treatment of stable mild or moderate chronic heart failure (CHF) in addition to standard therapies in elderly patients aged >or=70 years. Nebivolol is an effective antihypertensive agent and is well tolerated in patients with hypertension. The drug also effectively decreased the composite endpoint of mortality and cardiovascular hospital admission in elderly patients with CHF and was generally well tolerated in this population. Nebivolol should be considered as an alternative first-line treatment option for patients with uncomplicated mild to moderate essential hypertension and in elderly patients with CHF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink